VivoSeq
Oncology

Recurrent or Refractory Solid Tumors

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Recurrent or Refractory Solid Tumors is an early-stage landscape with 0 programs across 2 companies. The most active players are Erimos Pharmaceuticals, Shanghai PerHum Therapeutics Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

84/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Erimos Pharmaceuticals

0 programs

PreclinicalS

Shanghai PerHum Therapeutics Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

26

clinical trials

Completed21 · 81%
Terminated3 · 12%
Withdrawn1 · 4%
Unknown status1 · 4%

Clinical Trials

Trial Activity

26 trials

Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
Completed·National Cancer Institute (NCI)·Phase 1·NCT00077454·95 enrolled
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
Completed·Children's Oncology Group·Phase 1·NCT00107458·26 enrolled
Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)
Completed·EEndocyte·Phase 1·NCT00308269·32 enrolled
Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors
Completed·EErimos Pharmaceuticals·Phase 1·NCT00259818·30 enrolled
Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors
Completed·SState University of New York - Upstate Medical University·Phase 1·NCT00003555·20 enrolled
Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
Completed·MMontefiore Medical Center·Phase 1·NCT00004864
Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00003899
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
Completed·Children's Oncology Group·Phase 1·NCT00003597·16 enrolled
A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin
Completed·—·Phase 1·NCT00993044·13 enrolled
Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Completed·Children's Oncology Group·Phase 1·NCT02975882·33 enrolled
Irofulven in Treating Children With Recurrent or Refractory Solid Tumors
Completed·National Cancer Institute (NCI)·Phase 1·NCT00003370·12 enrolled
Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
Completed·MMontefiore Medical Center·Phase 1·NCT00004863·18 enrolled
L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors
Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003430·40 enrolled
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Completed·National Cancer Institute (NCI)·Phase 1·NCT01709435·41 enrolled
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Completed·National Cancer Institute (NCI)·Phase 1·NCT02780804·21 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)